ABBOTT INDIA
|
|
BOM : 500488     NSE : ABBOTINDIA     | |
LT :  
    Long Term Analysis
Fundamentals : Good
Valuation : Bad [Stock is Expensive] Debt : Low |
Updated: |
ST :  
    Short Term Analysis
Quarterly Earnings Trend : Upward
Price Momentum : Downward Pledged Shares : None or < 25% |
Apr 26,2024 |
Price(EOD): ₹ 25,864.80
This is the End-of-Day (EOD) Stock Price updated daily by 7 pm IST.
|
Pharmaceuticals & Drugs |
MCap: ₹ 54,833.38 Cr |
Industry Peers & Returns | 1W | 1M | 1Y |
ABBOTT INDIA | -1.5% | -4.5% | 13.9% |
SUN PHARMACEUTICAL INDUSTRIES | -2.3% | -6.5% | 55.3% |
CIPLA | 4.1% | -4.8% | 55.6% |
DR REDDYS LABORATORIES | 4% | 0.8% | 29.4% |
ZYDUS LIFESCIENCES | -1.2% | -5.2% | 83.9% |
DIVIS LABORATORIES | 7.8% | 17.4% | 20.3% |
MANKIND PHARMA | 1.3% | 7% | NA |
TORRENT PHARMACEUTICALS | 3.9% | 5.1% | 66.1% |
LUPIN | 0.6% | 0.5% | 127.2% |
FUNDAMENTAL ANALYSIS OF ABBOTT INDIA
 Y : Last Audited Annual/Yearly Data
TTM i.e. Trailing Twelve Months is calculated using last 4 quarterly data and is a good substitute to track last 4 Qtr Annual result before the subsequent year data is published and audited.
Learn More
VALUATION OF ABBOTT INDIA
 Ratio | Standalone | |
---|---|---|
P/E P/B P/S |
47.98
P/E Calculated based on Trailing Twelve Months (TTM) Earnings of Rs 1,145.58 Cr
[Latest Qtr - Dec2023 - Standalone Results ] 17.47
P/B Calculated based on Book Value of Rs 3,146.02 Cr
[Latest Year - Mar2023 - Standalone Results ] 9.55
P/S Calculated based on Trailing Twelve Months (TTM) Revenues of Rs 0.00 Cr
[Latest Qtr - Dec2023 - Standalone Results ] |
|
Financial Ratios → |
Model | Discount(-)/ Premium(+) |
---|---|
EV/EBIDTA EV/Sales Price/Sales |
78% 120% 117% |
SHARE PRICE MOMENTUM OF ABBOTT INDIA
ABBOTT INDIA vs SENSEX
DEBT OF ABBOTT INDIA
Year | Debt/Equity ratio | |
---|---|---|
Standalone | Consolidated | |
2023 2022 2021 Avg_3yrs |
0 0 0 - |
- - - - |
[Last Annual Data : Mar2023]
|
||
Financial Ratios → |
PLEDGED PROMOTER SHARES OF ABBOTT INDIA
Pledged Promoter Shares |
0 % | |
---|---|---|
As on : Dec2023 | ||
If less than 25% | Good |
|
If between 25% and 50% | Neutral | |
If greater than 50% | Bad | |
Shareholding Pattern → |
QTRLY RESULTS OF ABBOTT INDIA
Standalone | Q-o-Q | Y-o-Y |
---|---|---|
Revenue Op Profit Profit Before Tax Profit After Tax |
-3.81% 1.79% 1.62% -0.63% |
8.69% 24.18% 26.08% 25.99% |
QtrlyTrend |
4 | |
Latest Qtr: Dec2023 | ||
Quarterly Result Analysis → |
ABBOTT INDIA related INDICES
BSE Indices | 1W | 1M | 1Y |
---|---|---|---|
S&P BSE MIDSMALLCAP | 4% | 9.7% | 67.3% |
S&P BSE MID CAP | 4% | 7.6% | 67.4% |
S&P BSE 400 MIDSMALLCAP | 3.8% | 9.1% | 62% |
S&P BSE 150 MIDCAP | 3.6% | 7.7% | 59.6% |
S&P BSE HEALTHCARE | 3% | 4% | 55.2% |
NSE Indices | 1W | 1M | 1Y |
---|---|---|---|
NIFTY MID SMALL400 | 3.9% | 9.6% | 64.8% |
NIFTY MIDCAP150 | 3.7% | 8% | 60.4% |
NIFTY HEALTHCARE | 3.2% | 2.5% | 51.3% |
NIFTY PHARMA | 3.2% | 2.2% | 51.4% |
NIFTY500 MULTICAP 50:25:25 | 2.8% | 6.7% | 49.4% |
You may also like the below Video Courses
FAQ about ABBOTT INDIA
Is ABBOTT INDIA good for long term investment?
As on Apr 26,2024, the Fundamentals of ABBOTT INDIA look Strong and hence it may be good for long term investment! See Financial Performance of ABBOTT INDIA . Please look at the other parameters such as Valuation, Price Momentum, News & Corporate Governance and/or consult an Investment Advisor before taking an investment decision!Is ABBOTT INDIA UnderValued or OverValued?
As on Apr 26,2024, ABBOTT INDIA is Over Valued based on the estimates of intrinsic value and hence may not be a good buying opportunity according to Share Valuation at this time!What is the Intrinsic Value of ABBOTT INDIA ?
As on Apr 26,2024, the Intrinsic Value of ABBOTT INDIA is Rs. 11,932.08 estimated based on Median of the 3 historical models.Fair Value [Median EV / EBIDTA Model] : Rs. 14,560.52
Fair Value [Median EV / Sales Model] : Rs. 11,773.82
Fair Value [Median Price / Sales Model] : Rs. 11,932.08
Estimated Median Fair Value of ABBOTT INDIA : Rs. 11,932.08
The fair value of any stock is always subjective and should, in no way, be taken as a recommendation to buy/sell the same.